Novartis AG ADR (NVS)vsRxsight Inc (RXST)
NVS
Novartis AG ADR
$153.67
-0.26%
HEALTHCARE · Cap: $290.96B
RXST
Rxsight Inc
$6.25
-0.64%
HEALTHCARE · Cap: $253.76M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 44373% more annual revenue ($56.69B vs $127.48M). NVS leads profitability with a 22.5% profit margin vs -36.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RXST
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$153.67
$60.94 premium
Margin of Safety
+71.3%
Fair Value
$27.94
Current Price
$6.25
$21.69 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : RXST
The strongest argument for RXST centers on Price/Book, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : RXST
The primary concerns for RXST are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while RXST is a turnaround play — different risk/reward profiles.
RXST carries more volatility with a beta of 1.15 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 34/100), backed by strong 22.5% margins. RXST offers better value entry with a 71.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rxsight Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rxsight Inc. is a cutting-edge healthcare technology company dedicated to transforming vision correction through advanced diagnostic and surgical solutions in refractive eye surgery. By integrating proprietary software with precision laser systems, Rxsight aims to significantly improve patient outcomes and enhance the quality of life for those seeking vision correction. The company boasts a robust intellectual property portfolio and strategic collaborations that position it favorably within the growing ophthalmic market. Committed to innovation and operational excellence, Rxsight is poised to drive substantial advancements in eye care, reflecting its potential for sustained growth and impact in the sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?